Biovance Capital Partners

Profile

Biovance Capital Partners is a biotech investor based in Portugal, focusing on early-stage biopharma companies across Europe. Founded with a commitment to enhancing transformative medical treatments, the team comprises experienced professionals with backgrounds in academia and industry, including PhDs and MDs from institutions such as Harvard and Imperial College. Biovance leverages its extensive network to support pioneering entrepreneurs in bringing novel therapies to market. The firm is distinguished by its bespoke investment approach, tailored to the unique needs of biopharmaceutical ventures.

Biovance primarily invests in early-stage ventures, including seed and Series A rounds, with a strict focus on biotech companies involved in therapeutic development across all modalities. Typical investments range between $1-5 million, with support from the European Investment Fund and other public and private partners. Biovance Capital is committed to European coverage, with a special emphasis on Southern Europe. Its Fund I is €60 million, and the firm maintains a strategic partnership with international research institutes and accelerators.

Notable investments include Vaxdyn - specializing in vaccines, where Biovance Capital co-led a Series A round. The firm's portfolio showcases a blend of innovative therapeutics companies, indicating a focus on building long-term value through strategic collaborations and leveraging a clear regulatory pathway to market.